FUROSEMIDE | A202747 | BAXTER HEALTHCARE CORP
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from AKORN Specialty Generics FDA-2016-P-2375 · 5 docket documents AKORN Specialty Generics filed this citizen petition under Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act requesting that the FDA amend the Orange Book to designate Furosemide Injection 10 mg/mL ANDA 202747 manufactured by Claris as a reference listed drug, enabling AKORN to submit | 505(q) | 2016-08-02 | Open | AKORN Specialty Generics |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$0.4178
per ml
Lowest NADAC/Unit
$0.3189
per ml
Brand NDCs
0
Generic NDCs
3
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 36000028225FUROSEMIDE 20 MG/2 ML VIAL | $0.4178 | ML | Generic | — | 2026-06-17 |
| 36000028325FUROSEMIDE 40 MG/4 ML VIAL | $0.3189 | ML | Generic | — | 2026-06-17 |
| 72572019025FUROSEMIDE 40 MG/4 ML VIAL | $0.3189 | ML | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.